Oncotab, Inc
Publicly observedCharlotte, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Charlotte | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Oncotab, Inc | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | E5FXNY7GG5M5 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant1 Aug 2026Publicly observed
NIH SBIR/STTR award: Combination Therapy of T-Cell Engager and Chemotherapy for Pancreatic Cancer Treatment
USD 1,130,587.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
- Grant1 Jun 2025Publicly observed
NIH SBIR/STTR award: Optimized targeted radiotherapy of pancreatic cancer
USD 400,000.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.